Belite Bio uplists to Nasdaq Global Select Market

Belite Bio, Inc announced on October 19, 2026 that it received approval from Nasdaq to transfer the listing of its securities from the Nasdaq Capital Market to the Nasdaq Global Select Market.¹ Trading on the Nasdaq Global Select Market began at the market open on October 19, 2026, under the company's existing ticker symbol BLTE.¹

The Nasdaq Global Select Market is the highest of the three Nasdaq market tiers, and the uplisting reflects the company's compliance with that tier's more stringent financial and liquidity standards, along with progress in strengthening its financial profile and capital markets presence.¹ The company said the transition is expected to enhance its visibility among institutional investors, improve liquidity, and broaden market recognition.¹

Dr. Tom Lin, Belite Bio's Chairman and Chief Executive Officer, said the uplisting is a significant milestone for Belite Bio and reflects the company's ongoing financial discipline and business execution.¹ He added that the company would continue working to bring the potential first-ever approved treatment to patients living with Stargardt disease.¹

Belite Bio describes itself as a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases.¹ Its lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye.¹

According to the company, it has completed a Phase 3 trial called DRAGON in adolescent and adult subjects with STGD1, which met its primary endpoint, and tinlarebant is currently being evaluated in a Phase 2/3 trial called DRAGON II in adolescent and adult subjects with STGD1 and a Phase 3 trial called PHOENIX in subjects with GA.¹